http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-042132-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07b71571160c289fbf5fc680dfea513f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2602-08 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C229-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C229-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C217-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C217-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C217-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C217-54 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C217-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C229-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C217-34 |
| filingDate | 2003-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-042132-A1 |
| titleOfInvention | COMPOUND OF 2- HYDROXI -3- (2- ARIL - 1, 1 - DIMETHYLETHYLAMINE) PROPOXIFENILO, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES IT TO PREPARE IT |
| abstract | Calcilytic compound of 2-hydroxy-3- (2-aryl-1,1-dimethylethylamino) propoxyphenyl having the formula (1), in which: R1 and R5 are independently selected from the group consisting of H and halogen; R2, R3 and R4 are independently selected from the group consisting of H, halogen and J-K, wherein: j is a covalent bond, alkylene or alkenyl; and K is selected from the group of CO2R8, where R8H or alkyl; R6 is selected from the group consisting of H or alkyl; R7 is selected from the group consisting of condensed aryl or aryl, dihydro, condensed aryl tetrahydro, heteroaryl, unsubstituted or substituted with any substituents selected from the group consisting of OH, halogen, C1-4 alkyl, C1-4 alkoxy, C3 cycloalkyl -8, CF3, OCF3, CN and NO2; and pharmaceutically acceptable salts and complexes thereof. Pharmaceutical composition comprising a compound of the formula (1) together with pharmaceutically acceptable diluents or excipients. Use of the compound of the formula to prepare a pharmaceutical composition for the treatment of a disease or disorder comprising abnormal bone or mineral homeostasis or to increase serum parathyroid hormone levels in mammals by administration to a subject in need thereof. effective amount of said compound. |
| priorityDate | 2002-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.